Last updated: 16 June 2023 at 8:36pm EST

Kin-Hung Yu Net Worth




The estimated Net Worth of K Peony Yu is at least 16.6 百万$ dollars as of 15 June 2023. Kin Yu owns over 1,709 units of FibroGen Inc stock worth over 1,114$ and over the last 10 years he sold FGEN stock worth over 10,764,887$. In addition, he makes 5,856,450$ as Chief Medical Officer at FibroGen Inc.

Kin Yu FGEN stock SEC Form 4 insiders trading

Kin has made over 55 trades of the FibroGen Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 1,709 units of FGEN stock worth 684$ on 15 June 2023.

The largest trade he's ever made was selling 40,000 units of FibroGen Inc stock on 2 October 2017 worth over 2,185,200$. On average, Kin trades about 4,178 units every 33 days since 2014. As of 15 June 2023 he still owns at least 2,786 units of FibroGen Inc stock.

You can see the complete history of Kin Yu stock trades at the bottom of the page.





Kin-Hung Yu biography

Dr. Kin-Hung Peony Yu serves as Chief Medical Officer of the Company.D., is Chief Medical Officer of the Company. She served as our Vice President of Clinical Development from December 2008 until April 2016 when she was promoted to Chief Medical Officer. Dr. Yu brings to us expertise in design and execution of all phases of clinical development programs, including clinical and regulatory strategy, interactions with regulatory authorities in the United States and European Union, as well as experience with successful leadership of clinical teams. Prior to joining us, Dr. Yu was Vice President of Clinical Research at Anesiva, Inc., where she was responsible for management of clinical research, statistics/data management, clinical operations, and medical affairs/medical information for all clinical programs, including the late-stage clinical development and approval of Zingo®, a drug-device combination for pain management. Prior to Anesiva, Dr. Yu was Director, Clinical Development at ALZA Corporation (a subsidiary of Johnson & Johnson) where she was Global Clinical Lead for IONSYS®, a drug-device combination for post-operative pain, and led a successful New Drug Application resubmission with the U.S. Food and Drug Administration and multiple interactions with European regulatory authorities resulting in marketing approval in 25 European countries. Prior to ALZA, Dr. Yu held previous posts at Pain Therapeutics, Inc. and at Elan Pharmaceuticals. Dr. Yu received a Bachelor of Science degree in Chemical Engineering and a medical degree both from the University of California, Davis, followed by residency training at Stanford Medical School.

What is the salary of Kin Yu?

As the Chief Medical Officer of FibroGen Inc, the total compensation of Kin Yu at FibroGen Inc is 5,856,450$. There are no executives at FibroGen Inc getting paid more.



How old is Kin Yu?

Kin Yu is 57, he's been the Chief Medical Officer of FibroGen Inc since 2016. There are 13 older and 8 younger executives at FibroGen Inc. The oldest executive at FibroGen Inc is Thomas Kearns, 83, who is the Lead Independent Director.

What's Kin Yu's mailing address?

K's mailing address filed with the SEC is 25651, Atlantic Ocean Drive, Lake Forest, Orange County, California, 92630, United States.

Insiders trading at FibroGen Inc

Over the last 10 years, insiders at FibroGen Inc have traded over 188,593,537$ worth of FibroGen Inc stock and bought 106,523 units worth 1,309,423$ . The most active insiders traders include Rory B RiggsThomas B NeffJeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of 6,963$. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth 25,884$.



What does FibroGen Inc do?

fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.



What does FibroGen Inc's logo look like?

FibroGen Inc logo

Complete history of Kin Yu stock trades at FibroGen Inc、Staar Surgical Co

日付
#
会社
インサイダー
取引
取引
株式 1株当たりの株価 合計金額 その後の株式数 ソース
15 Jun 2023 K Peony Yu
ディレクター
オプション行使 1,709 52.67$ 90,013$
15 Jun 2023
2,786
16 Jun 2022 K Peony Yu
ディレクター
オプション行使 355 62.10$ 22,046$
16 Jun 2022
1,077
16 Dec 2020 K Peony Yu
Chief Medical Officer
販売 3,350 41.61$ 139,394$
16 Dec 2020
192,292
16 Sep 2020 K Peony Yu
Chief Medical Officer
販売 3,351 44.01$ 147,478$
16 Sep 2020
198,934
3 Sep 2020 K Peony Yu
Chief Medical Officer
オプション行使 10,000 18.00$ 180,000$
3 Sep 2020
215,576
24 Jul 2020 K Peony Yu
Chief Medical Officer
販売 3,351 42.35$ 141,915$
24 Jul 2020
205,576
6 Mar 2020 K Peony Yu
Chief Medical Officer
オプション行使 3,750 19.39$ 72,713$
6 Mar 2020
166,541
16 Dec 2019 K Peony Yu
Chief Medical Officer
販売 3,420 46.68$ 159,646$
16 Dec 2019
172,617
4 Dec 2019 K Peony Yu
Chief Medical Officer
オプション行使 4,157 17.46$ 72,581$
4 Dec 2019
179,397
16 Sep 2019 K Peony Yu
Chief Medical Officer
販売 3,419 40.92$ 139,905$
16 Sep 2019
175,240
12 Jun 2019 K Peony Yu
Chief Medical Officer
オプション行使 10,698 14.58$ 155,977$
12 Jun 2019
190,396
14 Mar 2019 K Peony Yu
Chief Medical Officer
販売 9,145 56.30$ 514,864$
14 Mar 2019
182,440
14 Dec 2018 K Peony Yu
Chief Medical Officer
販売 3,422 38.58$ 132,021$
14 Dec 2018
144,123
31 Aug 2018 K Peony Yu
Chief Medical Officer
オプション行使 6,800 12.29$ 83,572$
31 Aug 2018
154,269
3 Jul 2018 K Peony Yu
Chief Medical Officer
オプション行使 15,645 14.58$ 228,104$
3 Jul 2018
163,114
14 Jun 2018 K Peony Yu
Chief Medical Officer
販売 3,422 59.20$ 202,582$
14 Jun 2018
147,469
16 Apr 2018 K Peony Yu
Chief Medical Officer
販売 7,500 47.81$ 358,575$
16 Apr 2018
152,833
14 Mar 2018 K Peony Yu
Chief Medical Officer
販売 9,891 53.20$ 526,201$
14 Mar 2018
128,333
8 Feb 2018 K Peony Yu
Chief Medical Officer
販売 7,500 53.97$ 404,775$
8 Feb 2018
144,586
29 Jan 2018 K Peony Yu
Chief Medical Officer
販売 10,000 62.00$ 620,000$
29 Jan 2018
152,086
14 Dec 2017 K Peony Yu
Chief Medical Officer
販売 2,851 43.70$ 124,589$
14 Dec 2017
162,086
6 Nov 2017 K Peony Yu
Chief Medical Officer
販売 7,500 55.37$ 415,275$
6 Nov 2017
168,046
4 Oct 2017 K Peony Yu
Chief Medical Officer
オプション行使 15,000 14.58$ 218,700$
4 Oct 2017
190,546
2 Oct 2017 K Peony Yu
Chief Medical Officer
販売 40,000 54.63$ 2,185,200$
2 Oct 2017
175,546
14 Sep 2017 K Peony Yu
Chief Medical Officer
販売 2,851 51.00$ 145,401$
14 Sep 2017
185,546
21 Aug 2017 K Peony Yu
Chief Medical Officer
販売 7,500 41.03$ 307,725$
21 Aug 2017
191,507
8 Aug 2017 K Peony Yu
Chief Medical Officer
販売 37,500 50.58$ 1,896,750$
8 Aug 2017
199,007
1 Aug 2017 K Peony Yu
Chief Medical Officer
オプション行使 10,000 14.58$ 145,800$
1 Aug 2017
226,507
10 Jul 2017 K Peony Yu
Chief Medical Officer
販売 5,000 32.98$ 164,900$
10 Jul 2017
216,507
14 Jun 2017 K Peony Yu
Chief Medical Officer
販売 3,721 28.95$ 107,723$
14 Jun 2017
221,507
10 May 2017 K Peony Yu
Chief Medical Officer
販売 5,000 26.38$ 131,900$
10 May 2017
226,046
25 Apr 2017 K Peony Yu
Chief Medical Officer
オプション行使 5,000 14.58$ 72,900$
25 Apr 2017
236,046
25 Apr 2017 K Peony Yu
Chief Medical Officer
オプション行使 5,000 14.58$ 72,900$
25 Apr 2017
236,046
14 Mar 2017 K Peony Yu
Chief Medical Officer
販売 7,851 25.41$ 199,494$
14 Mar 2017
231,046
14 Mar 2017 K Peony Yu
Chief Medical Officer
販売 7,851 25.41$ 199,494$
14 Mar 2017
231,046
10 Jan 2017 K Peony Yu
Chief Medical Officer
販売 5,000 23.56$ 117,800$
10 Jan 2017
202,448
10 Jan 2017 K Peony Yu
Chief Medical Officer
販売 5,000 23.56$ 117,800$
10 Jan 2017
202,448
14 Dec 2016 K Peony Yu
Chief Medical Officer
販売 2,344 20.65$ 48,404$
14 Dec 2016
207,448
14 Dec 2016 K Peony Yu
Chief Medical Officer
販売 2,344 20.65$ 48,404$
14 Dec 2016
207,448
8 Nov 2016 K Peony Yu
Chief Medical Officer
オプション行使 4,700 4.91$ 23,077$
8 Nov 2016
211,202
8 Nov 2016 K Peony Yu
Chief Medical Officer
オプション行使 4,700 4.91$ 23,077$
8 Nov 2016
211,202
14 Sep 2016 K Peony Yu
Chief Medical Officer
販売 2,345 18.66$ 43,758$
14 Sep 2016
206,502
14 Sep 2016 K Peony Yu
Chief Medical Officer
販売 2,345 18.66$ 43,758$
14 Sep 2016
206,502
10 Jun 2016 K Peony Yu
Chief Medical Officer
販売 2,344 17.96$ 42,098$
10 Jun 2016
210,257
16 May 2016 K Peony Yu
Chief Medical Officer
販売 6,107 17.60$ 107,483$
16 May 2016
214,011
5 Feb 2016 K Peony Yu
Chief Medical Officer
オプション行使 10,500 4.55$ 47,775$
5 Feb 2016
187,095
10 Dec 2015 K Peony Yu
Chief Medical Officer
販売 1,093 28.96$ 31,653$
10 Dec 2015
176,595
25 Nov 2015 K Peony Yu
Chief Medical Officer
販売 5,000 30.00$ 150,000$
25 Nov 2015
178,345
17 Nov 2015 K Peony Yu
Chief Medical Officer
販売 5,000 28.00$ 140,000$
17 Nov 2015
183,345
9 Nov 2015 K Peony Yu
Chief Medical Officer
販売 5,000 25.62$ 128,100$
9 Nov 2015
187,904
19 Oct 2015 K Peony Yu
Chief Medical Officer
販売 5,000 24.00$ 120,000$
19 Oct 2015
192,904
15 Oct 2015 K Peony Yu
Chief Medical Officer
販売 5,000 21.46$ 107,300$
15 Oct 2015
197,904
10 Sep 2015 K Peony Yu
Chief Medical Officer
販売 1,093 27.84$ 30,429$
10 Sep 2015
202,904
6 Jul 2015 K Peony Yu
Chief Medical Officer
販売 5,381 22.69$ 122,095$
6 Jul 2015
204,654
14 May 2015 K Peony Yu
Chief Medical Officer
オプション行使 8,000 3.20$ 25,600$
14 May 2015
210,692


FibroGen Inc executives and stock owners

FibroGen Inc executives and other stock owners filed with the SEC include: